thiotepa has been researched along with Mucositis, Oral in 9 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty-eight women with responsive metastatic breast cancer received high-dose cyclophosphamide (3 to 6 g/m2 over 4 days), thiotepa (400 to 800 mg/m2), and novobiocin (0." | 9.08 | Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. ( Armstrong, DK; Chen, TL; Clarke, BV; Colvin, OM; Davidson, NE; Grochow, LB; Huelskamp, AM; Kennedy, MJ; Ohly, K, 1995) |
| "Paclitaxel, an effective chemotherapeutic agent in the management of breast carcinoma, may have activity in women whose disease has recurred after high dose chemotherapy." | 9.08 | A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma. ( Grinblatt, DL; Malloy, R; Williams, SF; Zimmerman, TM, 1998) |
| "Thiotepa is a common alkylating agent known to precipitate cutaneous reactions consistent with toxic erythema of chemotherapy, including erythema and hyperpigmentation." | 7.96 | Thiotepa hyperpigmentation preceding epidermal necrosis: malignant intertrigo misdiagnosed as Stevens-Johnson syndrome-toxic epidermal necrolysis overlap. ( Choate, EA; Sarantopoulos, GP; Truong, AK; Worswick, SD, 2020) |
| "The dose-limiting toxicities were interstitial pneumonitis and mucositis with moderately severe diarrhea (n = 3) and rash (n = 3)." | 6.69 | Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study. ( Blakey, D; Brettell, M; Briggs, P; Chapple, P; Eerhard, S; Gates, P; Januszewicz, EH; Juneja, S; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Seymour, JF; Toner, GC; Wolf, M, 2000) |
| "Thirty-eight women with responsive metastatic breast cancer received high-dose cyclophosphamide (3 to 6 g/m2 over 4 days), thiotepa (400 to 800 mg/m2), and novobiocin (0." | 5.08 | Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. ( Armstrong, DK; Chen, TL; Clarke, BV; Colvin, OM; Davidson, NE; Grochow, LB; Huelskamp, AM; Kennedy, MJ; Ohly, K, 1995) |
| "Paclitaxel, an effective chemotherapeutic agent in the management of breast carcinoma, may have activity in women whose disease has recurred after high dose chemotherapy." | 5.08 | A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma. ( Grinblatt, DL; Malloy, R; Williams, SF; Zimmerman, TM, 1998) |
| "Thiotepa is a common alkylating agent known to precipitate cutaneous reactions consistent with toxic erythema of chemotherapy, including erythema and hyperpigmentation." | 3.96 | Thiotepa hyperpigmentation preceding epidermal necrosis: malignant intertrigo misdiagnosed as Stevens-Johnson syndrome-toxic epidermal necrolysis overlap. ( Choate, EA; Sarantopoulos, GP; Truong, AK; Worswick, SD, 2020) |
| "The aim of the present study was to evaluate the correlation between the number of CD34+ cells transfused and the duration of hypoplasia, and the relationship between various CD34+ subsets (CD34+/33-; CD34+/38-; CD34+/ HLA-DR-; CD34+/Thy-1+) and engraftment kinetics in a series of patients with breast cancer treated with high doses of thiotepa and melphalan." | 3.70 | Relationships between total CD34+ cells reinfused, CD34+ subsets and engraftment kinetics in breast cancer patients. ( Baioni, M; Cariello, A; Dazzi, C; Ferrari, E; Fiorentini, G; Marangolo, M; Monti, G; Rosti, G; Scarpi, E; Zornetta, L, 2000) |
| "The dose-limiting toxicities were interstitial pneumonitis and mucositis with moderately severe diarrhea (n = 3) and rash (n = 3)." | 2.69 | Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study. ( Blakey, D; Brettell, M; Briggs, P; Chapple, P; Eerhard, S; Gates, P; Januszewicz, EH; Juneja, S; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Seymour, JF; Toner, GC; Wolf, M, 2000) |
| "Twelve patients with locally advanced breast carcinoma received HD-CT followed by peripheral stem cell reinfusion." | 2.68 | A new in vitro assay for quantitation of chemotherapy-induced mucositis. ( de Vries, EG; Mulder, NH; Sluiter, WJ; Spijkervet, FL; Timens, W; Timmer-Bosscha, H; van der Graaf, WT; Wymenga, AN, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Choate, EA | 1 |
| Sarantopoulos, GP | 1 |
| Worswick, SD | 1 |
| Truong, AK | 1 |
| Kremens, B | 1 |
| Gruhn, B | 1 |
| Klingebiel, T | 1 |
| Hasan, C | 1 |
| Laws, HJ | 1 |
| Koscielniak, E | 1 |
| Hero, B | 1 |
| Selle, B | 1 |
| Niemeyer, C | 1 |
| Finckenstein, FG | 1 |
| Schulz, A | 1 |
| Wawer, A | 1 |
| Zintl, F | 1 |
| Graf, N | 1 |
| Kennedy, MJ | 1 |
| Armstrong, DK | 1 |
| Huelskamp, AM | 1 |
| Ohly, K | 1 |
| Clarke, BV | 1 |
| Colvin, OM | 1 |
| Grochow, LB | 1 |
| Chen, TL | 1 |
| Davidson, NE | 1 |
| Gordon, B | 1 |
| Spadinger, A | 1 |
| Hodges, E | 1 |
| Ruby, E | 1 |
| Stanley, R | 1 |
| Coccia, P | 1 |
| Wymenga, AN | 1 |
| van der Graaf, WT | 1 |
| Spijkervet, FL | 1 |
| Timens, W | 1 |
| Timmer-Bosscha, H | 1 |
| Sluiter, WJ | 1 |
| de Vries, EG | 1 |
| Mulder, NH | 1 |
| Zimmerman, TM | 1 |
| Grinblatt, DL | 1 |
| Malloy, R | 1 |
| Williams, SF | 1 |
| Dazzi, C | 1 |
| Cariello, A | 1 |
| Rosti, G | 1 |
| Monti, G | 1 |
| Baioni, M | 1 |
| Zornetta, L | 1 |
| Ferrari, E | 1 |
| Scarpi, E | 1 |
| Fiorentini, G | 1 |
| Marangolo, M | 1 |
| Prince, HM | 1 |
| Rischin, D | 1 |
| Toner, GC | 1 |
| Seymour, JF | 1 |
| Blakey, D | 1 |
| Gates, P | 1 |
| Eerhard, S | 1 |
| Chapple, P | 1 |
| Quinn, M | 1 |
| Brettell, M | 1 |
| Juneja, S | 1 |
| Wolf, M | 1 |
| Januszewicz, EH | 1 |
| Richardson, G | 1 |
| Scarlett, J | 1 |
| Briggs, P | 1 |
| Ansfield, FJ | 1 |
| Carter, AC | 1 |
| Goldenberg, IS | 1 |
| Segaloff, A | 1 |
4 trials available for thiotepa and Mucositis, Oral
| Article | Year |
|---|---|
Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer.
Topics: Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophos | 1995 |
A new in vitro assay for quantitation of chemotherapy-induced mucositis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphami | 1997 |
A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 1998 |
Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diarrhea; | 2000 |
5 other studies available for thiotepa and Mucositis, Oral
| Article | Year |
|---|---|
Thiotepa hyperpigmentation preceding epidermal necrosis: malignant intertrigo misdiagnosed as Stevens-Johnson syndrome-toxic epidermal necrolysis overlap.
Topics: Aged; Antineoplastic Agents, Alkylating; Diagnostic Errors; Humans; Hyperpigmentation; Intertrigo; L | 2020 |
High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modal | 2002 |
Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis after hematopoietic stem-cell transplantation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 1994 |
Relationships between total CD34+ cells reinfused, CD34+ subsets and engraftment kinetics in breast cancer patients.
Topics: Adult; Analysis of Variance; Antigens, CD34; Breast Neoplasms; Female; Graft Survival; Hospitalizati | 2000 |
Phase I study of phenesterin (NSC-104469).
Topics: Administration, Oral; Adult; Aged; Androgens; Antineoplastic Agents; Blood Cell Count; Blood Platele | 1971 |